Cargando…
Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
CONTEXT: Considerable advances have been made in the first-line treatment of metastatic renal cell carcinoma (mRCC), with immunotherapy-based combinations including immunotherapy-tyrosine kinase inhibitors (IO-TKIs) and dual immunotherapy (IO-IO) favored. A lack of head-to-head clinical trials compa...
Autores principales: | Bosma, Nicholas A., Warkentin, Matthew T., Gan, Chun Loo, Karim, Safiya, Heng, Daniel Y.C., Brenner, Darren R., Lee-Ying, Richard M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792068/ https://www.ncbi.nlm.nih.gov/pubmed/35128482 http://dx.doi.org/10.1016/j.euros.2021.12.007 |
Ejemplares similares
-
Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis
por: Takemura, Kosuke, et al.
Publicado: (2022) -
Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models
por: Ouzaid, Idir, et al.
Publicado: (2022) -
Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era
por: Shah, Neil J., et al.
Publicado: (2023) -
The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype
por: Monda, Steven M., et al.
Publicado: (2023) -
Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)